Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Management of non-alcoholic fatty liver disease
Maria Letizia Petroni, Lucia Brodosi, Elisabetta Bugianesi, et al.
BMJ (2021), pp. m4747-m4747
Open Access | Times Cited: 148

Showing 1-25 of 148 citing articles:

Efficacy of peroxisome proliferator-activated receptor agonists, glucagon-like peptide-1 receptor agonists, or sodium-glucose cotransporter-2 inhibitors for treatment of non-alcoholic fatty liver disease: a systematic review
Alessandro Mantovani, Christopher D. Byrne, Giovanni Targher
˜The œLancet. Gastroenterology & hepatology (2022) Vol. 7, Iss. 4, pp. 367-378
Open Access | Times Cited: 171
Treatments for NAFLD: State of Art
Alessandro Mantovani, Andrea Dalbeni
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 5, pp. 2350-2350
Open Access | Times Cited: 164
Epidemiological trends and trajectories of MAFLD-associated hepatocellular carcinoma 2002–2033: the ITA.LI.CA database
Alessandro Vitale, Gianluca Svegliati‐Baroni, Alessio Ortolani, et al.
Gut (2021) Vol. 72, Iss. 1, pp. 141-152
Closed Access | Times Cited: 122
Metabolic dysfunction-associated fatty liver disease and implications for cardiovascular risk and disease prevention
Xiaodong Zhou, Jingjing Cai, Giovanni Targher, et al.
Cardiovascular Diabetology (2022) Vol. 21, Iss. 1
Open Access | Times Cited: 100
SGLT-2 Inhibitors in NAFLD: Expanding Their Role beyond Diabetes and Cardioprotection
Θεόδωρος Ανδρουτσάκος, Narjes Nasiri‐Ansari, Athanasios‐Dimitrios Bakasis, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 6, pp. 3107-3107
Open Access | Times Cited: 98
An international multidisciplinary consensus statement on MAFLD and the risk of CVD
Xiaodong Zhou, Giovanni Targher, Christopher D. Byrne, et al.
Hepatology International (2023) Vol. 17, Iss. 4, pp. 773-791
Open Access | Times Cited: 91
Mechanisms and possible hepatoprotective effects of glucagon-like peptide-1 receptor agonists and other incretin receptor agonists in non-alcoholic fatty liver disease
Giovanni Targher, Alessandro Mantovani, Christopher D. Byrne
˜The œLancet. Gastroenterology & hepatology (2023) Vol. 8, Iss. 2, pp. 179-191
Open Access | Times Cited: 74
Insights into Nonalcoholic Fatty-Liver Disease Heterogeneity
Marco Arrese, Juan Pablo Arab, Francisco Barrera, et al.
Seminars in Liver Disease (2021) Vol. 41, Iss. 04, pp. 421-434
Open Access | Times Cited: 78
MicroRNAs in the Pathogenesis of Nonalcoholic Fatty Liver Disease
Zhiqiang Fang, Guo‐Rui Dou, Lin Wang
International Journal of Biological Sciences (2021) Vol. 17, Iss. 7, pp. 1851-1863
Open Access | Times Cited: 58
Collective Social Correction: Addressing Misinformation through Group Practices of Information Verification on WhatsApp
Neta Kligler-Vilenchik
Digital Journalism (2021) Vol. 10, Iss. 2, pp. 300-318
Closed Access | Times Cited: 57
Harnessing reactive oxygen/nitrogen species and inflammation: Nanodrugs for liver injury
Min Liu, Qiong Huang, Yan Zhu, et al.
Materials Today Bio (2022) Vol. 13, pp. 100215-100215
Open Access | Times Cited: 56
Disulfiram ameliorates nonalcoholic steatohepatitis by modulating the gut microbiota and bile acid metabolism
Yuanyuan Lei, Li Tang, Qiao Chen, et al.
Nature Communications (2022) Vol. 13, Iss. 1
Open Access | Times Cited: 54
Bariatric Surgery Improves Nonalcoholic Fatty Liver Disease: Systematic Review and Meta-Analysis
Hui Zhou, Ping Luo, Pengzhou Li, et al.
Obesity Surgery (2022) Vol. 32, Iss. 6, pp. 1872-1883
Closed Access | Times Cited: 45
The pyruvate dehydrogenase complex: Life’s essential, vulnerable and druggable energy homeostat
Peter W. Stacpoole, Charles E. McCall
Mitochondrion (2023) Vol. 70, pp. 59-102
Open Access | Times Cited: 31
Severity and Remission of Metabolic Dysfunction–Associated Fatty/Steatotic Liver Disease With Chronic Kidney Disease Occurrence
Jingli Gao, Yuhao Li, Yijun Zhang, et al.
Journal of the American Heart Association (2024) Vol. 13, Iss. 5
Open Access | Times Cited: 11
Hepatic‐Accumulated Obeticholic Acid and Atorvastatin Self‐Assembled Nanocrystals Potentiate Ameliorative Effects in Treatment of Metabolic‐Associated Fatty Liver Disease
Huanfen Lu, Zhenglan Ban, Kai Xiao, et al.
Advanced Science (2024) Vol. 11, Iss. 10
Open Access | Times Cited: 10
Metabolic dysfunction-associated steatotic liver disease heterogeneity: Need of subtyping
Shahid Habib
World Journal of Gastrointestinal Pathophysiology (2024) Vol. 15, Iss. 2
Open Access | Times Cited: 10
NAFLD Fibrosis Progression and Type 2 Diabetes: The Hepatic–Metabolic Interplay
Simona Cernea
Life (2024) Vol. 14, Iss. 2, pp. 272-272
Open Access | Times Cited: 8
From fatty liver to fibrosis: the impact of miRNAs on NAFLD and NASH
Reda Mansour, Sherif S Abdel Mageed, Ahmed I. Abulsoud, et al.
Functional & Integrative Genomics (2025) Vol. 25, Iss. 1
Closed Access | Times Cited: 1
Circulating trimethylamine‐N‐oxide is associated with all‐cause mortality in subjects with nonalcoholic fatty liver disease
Jose L. Flores‐Guerrero, Adrian Post, Peter R. van Dijk, et al.
Liver International (2021) Vol. 41, Iss. 10, pp. 2371-2382
Open Access | Times Cited: 43
Developing an Innovative Pandemic Treaty to Advance Global Health Security
Lawrence O. Gostin, Benjamin Mason Meier, Barbara Stocking
The Journal of Law Medicine & Ethics (2021) Vol. 49, Iss. 3, pp. 503-508
Closed Access | Times Cited: 42
How Far beyond Diabetes Can the Benefits of Glucagon-like Peptide-1 Receptor Agonists Go? A Review of the Evidence on Their Effects on Hepatocellular Carcinoma
Konstantinos Arvanitakis, Theocharis Koufakis, Kalliopi Kotsa, et al.
Cancers (2022) Vol. 14, Iss. 19, pp. 4651-4651
Open Access | Times Cited: 30
Canagliflozin and Metabolic Associated Fatty Liver Disease in Patients With Diabetes Mellitus: New Insights From CANVAS
Angel N. Borisov, Alexander Kutz, Emanuel Christ, et al.
The Journal of Clinical Endocrinology & Metabolism (2023) Vol. 108, Iss. 11, pp. 2940-2949
Open Access | Times Cited: 22
The Emerging Therapeutic Potential of Kisspeptin and Neurokinin B
Bijal Patel, Kanyada Koysombat, Edouard Mills, et al.
Endocrine Reviews (2023) Vol. 45, Iss. 1, pp. 30-68
Open Access | Times Cited: 20
A Healthful Plant-Based Diet as an Alternative Dietary Approach in the Management of Metabolic Dysfunction-Associated Steatotic Liver Disease
Gabriele Castelnuovo, Nuria Pérez-Díaz-del-Campo, Chiara Rosso, et al.
Nutrients (2024) Vol. 16, Iss. 13, pp. 2027-2027
Open Access | Times Cited: 8
Page 1 - Next Page

Scroll to top